Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

• Status: Completed
• Trial end date: 2021-01-07
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ionis Pharmaceuticals, Inc.
• Collaborator: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Satisfactory completion of dosing & efficacy assessments in ISIS 420915-CS2

Exclusion Criteria:

• Any new condition or worsening of existing condition that could make the patient unsuitable for participation, or interfere with the patient participating in and/or completing the study